STRO Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue $9.84M; Research and development $31.70M; Operating expenses $39.73M; Income tax $1.00K.
- 2026-03-31: Revenue $14.52M; Research and development $36.55M; Operating expenses $44.18M; Income tax -$15.00K.
- 2025-12-31: Revenue $11.65M*; Research and development $36.64M*; Operating expenses $49.70M*; Income tax -$82.00K*.
- 2025-09-30: Revenue $9.69M; Research and development $39.85M; Operating expenses $58.15M; Income tax $0.00.
Consolidation item
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Related Party Transactions By Related Party
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Type Of Arrangement
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue | Research and development | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|
| 2026-06-30 | $9.84M | $31.70M | $39.73M | $1.00K | -$38.53M |
| 2026-03-31 | $14.52M | $36.55M | $44.18M | -$15.00K | -$38.48M |
| 2025-12-31 | $11.65M* | $36.64M* | $49.70M* | -$82.00K* | -$46.68M* |
| 2025-09-30 | $9.69M | $39.85M | $58.15M | $0.00 | -$56.86M |
| 2025-06-30 | $63.74M | $38.33M | $67.09M | -$18.00K | -$11.50M |
| 2025-03-31 | $17.40M | $51.60M | $85.91M | $7.00K | -$75.97M |
| 2024-09-30 | $8.52M | $62.11M | $76.44M | $0.00 | -$48.79M |
| 2024-06-30 | $25.71M | $62.02M | $74.39M | $8.00K | -$48.02M |
| 2024-03-31 | $13.01M | $56.88M | $69.60M | (m) | -$58.21M |
| 2023-09-30 | $16.92M | $45.67M | $60.94M | $1.84M | -$49.28M |
| 2023-06-30 | $10.41M | $41.59M | $56.59M | $151.00K | -$38.52M |
| 2023-03-31 | $12.67M | $39.40M | $54.91M | $395.00K | -$50.05M |
| 2022-09-30 | $25.15M | $31.71M | $46.36M | (m) | -$19.49M |
| 2022-06-30 | $28.10M | $32.33M | $47.48M | $2.50M | -$26.01M |
| 2022-03-31 | $5.90M | $29.99M | $45.03M | $0.00 | -$39.11M |
| 2021-09-30 | $8.52M | $26.60M | $43.19M | (m) | -$30.90M |
| 2021-06-30 | $28.05M | $25.31M | $37.85M | (m) | -$6.15M |
| 2021-03-31 | $14.66M | $22.56M | $33.67M | (m) | -$30.36M |
| 2020-12-31 | $8.28M | (m) | (m) | (m) | -$59.54M |
| 2020-09-30 | $17.82M | $19.36M | $28.44M | (m) | $17.14M |
| 2020-06-30 | $9.47M | $17.24M | $25.89M | (m) | $29.87M |
| 2020-03-31 | $7.15M | $17.62M | $26.33M | (m) | -$19.59M |
| 2019-12-31 | $11.30M | (m) | (m) | (m) | -$14.79M |
| 2019-09-30 | $12.28M | $16.90M | $25.01M | (m) | -$12.91M |
| 2019-06-30 | $10.53M | $16.14M | $24.21M | (m) | -$13.79M |
| 2019-03-31 | $8.63M | $15.18M | $22.89M | (m) | -$14.25M |
| 2018-12-31 | $19.09M | (m) | (m) | (m) | -$1.49M |
| 2018-09-30 | $7.84M | $12.64M | $17.99M | (m) | -$10.24M |
| 2018-06-30 | $5.70M | $13.75M | $17.79M | (m) | -$11.54M |
| 2018-03-31 | $5.79M | $13.08M | $17.50M | (m) | -$12.05M |
| 2017-12-31 | $4.04M | (m) | (m) | (m) | -$15.34M |
| 2017-09-30 | $17.50M | $13.67M | $18.56M | (m) | -$1.42M |
| 2017-06-30 | $15.36M | (m) | (m) | (m) | -$1.81M |
| 2017-03-31 | $14.85M | (m) | (m) | (m) | -$1.11M |
Revenue and expense 6 month
| Period end | Revenue | Research and development | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|
| 2026-06-30 | $24.36M | $68.25M | $83.91M | -$14.00K | -$77.02M |
| 2025-06-30 | $81.14M | $89.92M | $153.00M | -$11.00K | -$87.47M |
| 2024-06-30 | $38.71M | $118.90M | $143.99M | $8.00K | -$106.23M |
| 2023-06-30 | $23.09M | $80.99M | $111.50M | $546.00K | -$88.57M |
| 2022-06-30 | $33.99M | $62.32M | $92.50M | $2.50M | -$65.12M |
| 2021-06-30 | $42.71M | $47.87M | $71.52M | (m) | -$36.51M |
| 2020-06-30 | $16.62M | $34.86M | $52.22M | (m) | $10.28M |
| 2019-06-30 | $19.15M | $31.32M | $47.10M | (m) | -$28.04M |
| 2018-06-30 | $11.50M | $26.83M | $35.29M | (m) | -$23.59M |
Revenue and expense 9 month
| Period end | Revenue | Research and development | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|
| 2025-09-30 | $90.84M | $129.78M | $211.16M | -$11.00K | -$144.32M |
| 2024-09-30 | $47.23M | $181.01M | $220.43M | $8.00K | -$155.02M |
| 2023-09-30 | $40.01M | $126.66M | $172.44M | $2.38M | -$137.86M |
| 2022-09-30 | $59.14M | $94.04M | $138.86M | $2.50M | -$84.61M |
| 2021-09-30 | $51.23M | $74.47M | $114.71M | (m) | -$67.41M |
| 2020-09-30 | $34.44M | $54.22M | $80.66M | (m) | $27.42M |
| 2019-09-30 | $31.43M | $48.22M | $72.12M | (m) | -$40.95M |
| 2018-09-30 | $19.33M | $39.48M | $53.28M | (m) | -$33.82M |
| 2017-09-30 | $47.70M | $39.50M | $51.80M | (m) | -$4.34M |
Revenue and expense 12 month
| Period end | Revenue | Research and development | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|
| 2025-12-31 | $102.48M | $166.42M | $260.85M | -$93.00K | -$191.00M |
| 2024-12-31 | $62.04M | $252.04M | $300.50M | $2.36M | -$227.00M |
| 2023-12-31 | $153.73M | $180.43M | $243.01M | $18.19M | -$107.00M |
| 2022-12-31 | $67.77M | $137.17M | $196.72M | $2.50M | -$119.20M |
| 2021-12-31 | $61.88M | $104.40M | $160.40M | $0.00 | -$105.54M |
| 2020-12-31 | $42.72M | $76.96M | $113.78M | $103.00K | -$32.13M |
| 2019-12-31 | $42.74M | $65.61M | $98.20M | $0.00 | -$119.20M |
| 2018-12-31 | $38.42M | $54.26M | $75.64M | $0.00 | -$35.32M |
| 2017-12-31 | $51.74M | $54.64M | $71.01M | $0.00 | -$19.69M |
| 2016-12-31 | $59.73M | $43.55M | $58.37M | (m) | $1.70M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |